Travoprost 0.004% ophthalmic solution

DRUG6 trials

Sponsors

Alcon Research, Novartis Pharmaceuticals, Kasr El Aini Hospital

Conditions

GlaucomaOcular HypertensionOpen Angle GlaucomaOpen-Angle GlaucomaOpen-angle GlaucomaPrimary Open Angle Glaucoma

Phase 4

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

CompletedNCT01464424

Alcon ResearchGlaucoma, Ocular Hypertension, Open-Angle Glaucoma

Start: 2011-10-31End: 2012-06-30Updated: 2013-09-13

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

CompletedNCT01664039

Alcon ResearchGlaucoma, Ocular Hypertension

Start: 2012-09-30End: 2014-06-30Updated: 2015-08-03

Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®

CompletedNCT01937299

Alcon ResearchOcular Hypertension, Open Angle Glaucoma

Start: 2013-10-31End: 2014-04-30Updated: 2015-05-14

Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma

CompletedNCT03150160

Novartis PharmaceuticalsGlaucoma

Start: 2017-09-21End: 2017-12-04Updated: 2019-02-25

Unknown Phase

A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution

TerminatedNCT01485822

Alcon ResearchOpen-angle Glaucoma

Start: 2004-07-31End: 2012-02-29Updated: 2013-05-14

Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients

CompletedNCT04461249

Kasr El Aini HospitalPrimary Open Angle Glaucoma

Start: 2019-06-01End: 2020-04-01Updated: 2020-07-08

Related Papers

Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.

2014-11-287 citations